Notified Continues 2023 Momentum, Recognized for Groundbreaking AI-Powered Solution for Communicators 17-10-2023, 03:15

Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26

Sostravel.com to Webcast Live at 2-02-2023, 20:36